Lysosomal Storage Diseases Market 2022 Growth Factors, Opportunities, Ongoing Trends and Key Players 2032
Lysosomal Storage Diseases Market : Hospitals End User Segment Anticipated to Account for 66.9% Revenue Share by 2016 End
Persistence Market Research delivers key insights on the global lysosomal storage diseases therapeutics market in a new report titled, “Lysosomal Storage Diseases Therapeutics Market: Global Industry Analysis and Forecast, 2016–2026”. In terms of revenue, the global lysosomal storage diseases therapeutics market is projected to register a healthy CAGR of 10.0% over the forecast period and is estimated to be valued at US$ 14.36 Bn by 2026. In the report, Persistence Market Research analyzes the key factors and trends impacting the growth and performance of the global lysosomal storage diseases therapeutics market over the forecast period.
Request For Free Sample Report of “Lysosomal Storage Diseases Market”@ https://www.persistencemarketresearch.com/samples/3145
Drivers and trends influencing the market
An increasing diagnosis rate due to increasing awareness and financial incentives for orphan drug development to recover R&D costs is the primary factor fueling the growth of the global lysosomal storage diseases therapeutics market. Also, an increasing focus of major biopharmaceutical companies on the research and development of drugs for the treatment of rare diseases is expected to boost the global lysosomal storage diseases therapeutics market during the forecast period. Moreover, the number of treatment options currently in the pipeline is further expected to bolster revenue growth of the global lysosomal storage diseases therapeutics market during the forecast period.
However, heterogeneity of the disease leading to underdiagnoses of lysosomal storage diseases, lack of treatment options, and high cost of treatment are factors likely to hamper the growth of the global lysosomal storage diseases therapeutics market over the forecast period.
Companies
- Shire PLC
- Pfizer, Inc.
- Sanofi
- BioMarin Pharmaceutical Inc.
- Actelion Ltd.
- Raptor Pharmaceutical Corp.
- Protalix Biotherapeutics Inc.
- Amicus Therapeutics, Inc.
- Others
Buy Full Report Now and Get Up to 20% Discount @ https://www.persistencemarketresearch.com/checkout/3145
PMR’s report titled “Private Healthcare Market: U.K. Industry Analysis, 2012 – 2016 and Forecast, Market forecast
The global lysosomal storage diseases therapeutics market has been segmented on the basis of Indication (Gaucher’s Diseases, Fabry Diseases, Pompe’s Syndrome, Mucopolysaccharidosis, Others); Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Others); End User (Hospitals, Clinics); and Region (North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA)).
The Gaucher’s Diseases indication segment is estimated to account for 29.7% revenue share of the global lysosomal storage diseases therapeutics market by 2016 end. The Enzyme Replacement Therapy segment was valued at US$ 4,833.8 Mn in 2015 and is expected to exhibit the highest CAGR of 10.0% over the forecast period to reach US$ 13.58 Bn by 2026 end. The Hospitals end user segment is expected to witness 2.8X increase in revenue over the forecast period and is expected to create absolute $ opportunity of US$ 346.2 Mn in 2017 over 2016.
Among regions, Europe is expected to be the dominant regional market in the global lysosomal storage diseases therapeutics market during the forecast period. The Europe market accounted for the highest revenue share of 34.8% and was valued at US$ 1,773.2 Mn in 2015; and is expected to witness a CAGR of 10.2% during the forecast period. North America is expected to be the second most lucrative market in the global lysosomal storage diseases therapeutics market and is estimated to represent absolute $ opportunity of US$ 159.6 Mn in 2017 over 2016.
Request Customization @ https://www.persistencemarketresearch.com/request-customization/3145
Vendor information
Shire PLC, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., and Amicus Therapeutics, Inc. are some of the companies operating in the global lysosomal storage diseases therapeutics market.
Top market players are investing in focused R&D initiatives to develop innovative products for the treatment of rare diseases and are looking to drive growth in established markets through strategic partnerships, collaborations, and acquisitions. The report discusses individual strategies of these companies in terms of increasing focus on rare diseases, initiatives to increase awareness, and enhancing distribution base. The report concludes with strategic recommendations for players already present in the market and new players planning to enter the global lysosomal storage diseases therapeutics market.
Key Questions Answered in This Report.
- What are the Roadblocks for Lysosomal Storage Diseases Market Suppliers?
- What are the Key Opportunities for Lysosomal Storage Diseases Market Manufacturers?
- How is Focus on Safety Influencing Lysosomal Storage Diseases Market Demand?
- What is the Regulatory Impact on Global Sales of Lysosomal Storage Diseases Market?
- Which Region Offers the Largest Opportunity for Sales of Lysosomal Storage Diseases Market?
- Where Does the U.S. Stand in the Market for Lysosomal Storage Diseases Market?
- What Is the Outlook for Lysosomal Storage Diseases Market Manufacturers in China?
- Why is Germany a Lucrative Market for Lysosomal Storage Diseases Market Manufacturers?
- Why Will Belgium Outpace Other European Markets for Lysosomal Storage Diseases Market?
- Why is There High Demand for Tires in Lysosomal Storage Diseases Market?
- Why are Sales of Lysosomal Storage Diseases Market Surging?
Related Market Reports:
The study also includes statistics as well as facts related to the macroeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the real-time PCR (qPCR) market..
Sleep Aid Devices Market is anticipated to account for over US$ 29,200 Mn, in terms of value, by 2026 end. The report on the sleep aid devices market further projects significant growth potential with CAGR at 4.9% through 2026..
About Us
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
Contact Us:
Persistence Market Research
Japan
Persistence Market Research
1-2-1 Kinshi Arca Central Building 14/F Tokyo, 130-0013 Japan
Call 0800-222-1088
United States
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]
This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on [email protected]
Published Mon, 28 Nov 2022 20:27:04 -0600
Comments are closed.